Group 1 - The A-share market for innovative drugs is experiencing significant gains, with companies like Meinohua, Wanbangde, and Lianhuan Pharmaceutical hitting the 10% daily limit, while Ketaobiotech saw a remarkable 20% increase [1] - As of March 21, 2026, the total value of China's innovative drug outbound business development (BD) contracts has reached $57.1 billion, with an upfront payment of $3.3 billion and a total of 53 contracts, representing 41% of the total for 2025, surpassing the entire year of 2024 [1] - Several leading innovative drug companies have confirmed a turning point in profitability, with Hengrui Medicine projecting that nearly 60% of its revenue will come from innovative drugs by 2025, and a growth forecast of over 30% for 2026 [1] Group 2 - The 2026 government work report has significantly elevated the strategic position of the biopharmaceutical industry, placing it alongside integrated circuits and aerospace as a new pillar industry for the nation [1] - Notable companies such as Nuocheng Jianhua, Yunding Xinyao, and Jingtai Holdings are expected to achieve profitability in 2025 [1]

Group 1 - The 180ESGETF Industrial Bank (510990) opened at a price of 0.999 yuan, experiencing a decline of 0.70% [1][2] - Major holdings of the 180ESGETF include Kweichow Moutai, which opened down 0.08%, and Ping An of China, which rose by 0.11% [1][2] - The fund's performance benchmark is the CSI 180 ESG Index return, managed by ICBC Credit Suisse Asset Management Company, with a fund manager named Li Ruimin [1][2] Group 2 - Since its establishment on June 18, 2021, the fund has achieved a return of 0.48%, while its return over the past month has been -6.81% [1][2]

Investment Rating - The report maintains a "Recommended" rating for the company [3]. Core Insights - The company achieved a record high in revenue and profit, with a total revenue of 316.29 billion yuan in 2025, representing a year-on-year growth of 13.02%. The net profit attributable to shareholders reached 77.11 billion yuan, up 21.69% year-on-year [6]. - The sales of innovative drugs significantly contributed to the revenue growth, with innovative drug sales reaching 163.42 billion yuan, a 26.09% increase year-on-year, accounting for 58.34% of total drug sales [6]. - The company is focusing on accelerating the internationalization of its innovative drugs, with licensing income becoming a new growth engine, generating 33.92 billion yuan in revenue during the reporting period [6]. - The report anticipates that the company's net profit attributable to shareholders will grow to 95.19 billion yuan in 2026, reflecting a 23% year-on-year increase, with projected EPS of 1.43 yuan [6][7]. Financial Performance Forecast - Revenue is projected to grow from 31,629 million yuan in 2025 to 38,145 million yuan in 2026, with a growth rate of 20.60% [2]. - The net profit is expected to increase from 7,711 million yuan in 2025 to 9,519 million yuan in 2026, with a growth rate of 23.45% [7]. - The gross margin is forecasted to remain stable, with a slight decrease from 86.21% in 2025 to 85.86% in 2026 [7]. Revenue Breakdown - Innovative drug sales are expected to exceed 30% growth in 2026, driven by strong performance in oncology products and new market entries [6]. - The company’s generic drug revenue has slightly declined due to ongoing impacts from national and local procurement policies, but new products have shown some growth [6]. Valuation Metrics - The report indicates that the current stock price corresponds to a PE ratio of 44 for 2026, 36 for 2027, and 30 for 2028 [6][7].

Summary of the Conference Call for 恒瑞医药 Company Overview - **Company**: 恒瑞医药 (Hengrui Medicine) - **Date of Call**: March 26, 2026 Key Points Industry and Company Insights - **Core Engine of Growth**: By 2025, innovative drug revenue is projected to reach 16.3 billion yuan (+26%), accounting for 58.34% of total revenue. The target for 2026 is to exceed 30% growth, significantly offsetting revenue declines from generic drug procurement policies [2][4] - **Medicare Inclusion**: By the end of 2025, 20 products/indications will be included in Medicare, a significant increase from the beginning of the year. Key products like HER2 ADC, JAK1 inhibitors, and PCSK9 monoclonal antibodies are expected to see rapid growth in 2026 [2] - **Business Development (BD) Normalization**: Since 2023, potential overseas transaction amounts have reached 27 billion USD. A collaboration prepayment with GSK will confirm approximately 250 million USD in 2026, with ongoing milestone payments and sales commissions [2][4] Research and Development Strategy - **Focus on Best-in-Disease**: The R&D strategy emphasizes ADC/AXC, targeted delivery, and small nucleic acid platforms, aiming to overcome challenges in extrahepatic delivery technology. It is expected that 53 new products/indications will be approved between 2026 and 2028 [2][5] - **Differentiated Layout in Metabolic Diseases**: Addressing weight loss quality and compliance issues with GLP-1 drugs, the company is developing APC (antibody-peptide conjugates) and has entered the data focus period for GLP-1/GIP dual-target and oral small molecule drugs for type 2 diabetes [2][6] Financial Performance and Projections - **Decline in Generic Drug Revenue**: The revenue from generic drugs is expected to decline due to national and local procurement policies, with a strategic reduction in investment in certain generic drug varieties. The overall trend is a gradual decrease, as reflected in past financial reports [3][4] - **Projected Revenue Growth**: The innovative drug sales revenue is expected to reach 16.3 billion yuan in 2025, with a 26% year-on-year increase, and the proportion of innovative drugs in total sales is expected to rise [3][4] Product Pipeline and Market Strategy - **Key Products for 2026**: The company anticipates significant growth from products like the HER2 ADC for non-small cell lung cancer and the long-acting PCSK9 monoclonal antibody. The pipeline includes 24 first-class new drugs and 5 second-class new drugs under development [7][8] - **Commercialization Strategy**: The establishment of a biopharmaceutical division aims to drive growth in both oncology and chronic disease sectors. The company is also focusing on grassroots market teams to enhance market penetration [9][10] Collaboration and Internationalization - **BD Collaboration Focus**: The company will continue to emphasize BD collaborations, particularly with late-stage products nearing approval, while also advancing its own overseas clinical trials [12] - **International Market Expansion**: The company is actively pursuing internationalization strategies, including establishing a research center in Boston and exploring the possibility of building sales teams and production bases overseas [12] Clinical Data and Future Outlook - **Upcoming Clinical Data Releases**: In 2026, approximately 25 phase III clinical data readouts are expected, with significant attention on ADC products and key non-oncology projects [13] - **Long-term R&D Goals**: The company plans to push 20 new molecules into clinical stages annually, ensuring robust growth momentum for future pipelines [13] Financial Metrics and Valuation - **Fair Value Changes**: In 2025, the company reported a fair value change income of approximately 25 million USD, primarily driven by equity investments [14] - **RAS Target Pipeline**: The company has established a comprehensive RAS pipeline, with ongoing developments in G12D inhibitors and plans for Pan-RAS inhibitors to address various cancer mutations [15] Small Nucleic Acid Development - **Platform Strategy**: The company is focusing on small nucleic acids, particularly in overcoming challenges in extrahepatic delivery, and plans to increase investment in this area significantly [15] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting the company's focus on innovation, market expansion, and addressing emerging healthcare needs.

Core Viewpoint - Heng Rui Medicine (600276.SH; 01276.HK) reported a continued double-digit growth in its annual performance for 2025, with total revenue reaching 31.629 billion yuan, a year-on-year increase of 13.02%, and a net profit attributable to shareholders of 7.711 billion yuan, up 21.69% [2]. Group 1: Revenue Growth - The growth in performance is primarily driven by the innovative drug segment, which achieved sales revenue of 16.342 billion yuan, a year-on-year increase of 26.09%, accounting for 58.34% of total drug sales revenue [3]. - Within the innovative drug sales, anti-tumor products generated revenue of 13.240 billion yuan, up 18.52%, representing 81.02% of the total innovative drug sales, while non-tumor products reached 3.102 billion yuan, growing by 73.36%, making up 18.98% of the total [3]. Group 2: Product and Market Expansion - In 2025, 20 products/indications of Heng Rui Medicine were included in the updated National Medical Insurance Directory, with 10 products entering the insurance coverage for the first time, leading to significant sales growth for some innovative drugs [4]. - Notable growth was observed in the sales of innovative anti-tumor drugs such as Rivoceranib and Darlisilib, as well as non-tumor products like Empagliflozin and Remimazolam, which benefited from clinical advantages [4]. Group 3: Licensing and Challenges - Revenue from external licensing of innovative drugs reached 3.392 billion yuan in 2025, contributing significantly to the company's overall revenue [4]. - Despite the transition towards innovative drugs, the revenue from the generic drug segment has slightly declined due to domestic centralized procurement policies [4]. - Currently, Heng Rui Medicine has not yet received approval for any innovative drugs in overseas markets but is actively pursuing independent development and registration abroad, with new clinical research centers established in Boston, USA [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2026年3月26日 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-05 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-054 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司福建盛迪医 药有限公司收到国家药品监督管理局（以下简称"国家药监局"）核准签发关于 HRS9531 注射液的《药物临床试验批准通知书》，将于近期开展临床试验。现将 相关情况公告如下： 一、药物的基本情况 药物名称：HRS9531 注射液 剂 型：注射剂 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2026 年 1 月 7 日受理的 HRS9531 注射液临床试验申请符合药品注册的有关要求，同意 本品开展临床试验。申请的适应症：用于降低动脉粥样硬化性心血管疾病患者的 主要心血管不良事件风险。 二、药物的其他情况 HRS9531 注射液是以 HRS9531 为主要活性成分，具有全球自主知识产权的新 型靶向抑胃肽受体（GIPR）和胰高血糖素样肽-1 受体（GLP-1R）的双激动剂， 可在体内调节糖脂代谢、抑制食欲和增强胰岛素敏感性，从而起到改善血糖和减 轻体重的效果。对于降低动脉粥样硬化性心血管疾病患者的 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Views - The company achieved a revenue of 31.63 billion RMB in 2025, representing a year-on-year growth of 13.0%, with a net profit attributable to shareholders of 7.71 billion RMB, up 21.7% year-on-year [1] - The company expects a significant acceleration in innovative drug revenue starting in 2026, projected to exceed 30% growth, driven by the inclusion of multiple innovative drugs in the national medical insurance [1][2] - The company has a strong pipeline with 8 innovative drugs and 6 new indications approved in 2025, and anticipates further approvals in the coming years [2] Financial Performance - In 2025, the company reported a decline in the overall revenue from generic drugs, which impacted the overall performance, but innovative drug revenue reached 16.34 billion RMB, growing 26.1% year-on-year [1] - The company’s net profit margin improved to 24.4% in 2025, an increase of 1.8 percentage points year-on-year, with expectations for continued improvement in 2026 as innovative drug revenue increases [3] - The company’s expenses as a percentage of sales, management, and R&D decreased in 2025, contributing to the improved net profit margin [3] Business Development (BD) Contributions - The company has completed 12 BD transactions from 2023 to 2025, totaling nearly 28 billion USD, which is expected to provide ongoing cash flow [4] - The company has over 30 products in clinical development that are among the top three globally for their targets, indicating potential for double-digit growth in BD revenue [4] Profit Forecast and Valuation - The forecast for net profit attributable to shareholders for 2026-2028 is 9.78 billion RMB, 12.62 billion RMB, and 16.64 billion RMB respectively, with corresponding EPS of 1.47 RMB, 1.90 RMB, and 2.51 RMB [5] - The company is valued at 591.8 billion RMB and 650.9 billion HKD, with target prices set at 89.16 RMB and 98.06 HKD [5]

Investment Rating - The investment rating for the company is "Buy" [7] Core Views - The company achieved a revenue of 31.63 billion RMB in 2025, representing a year-on-year growth of 13.0%, with a net profit attributable to shareholders of 7.71 billion RMB, up 21.7% year-on-year [1] - The company expects a significant acceleration in innovative drug revenue growth starting in 2026, projected to exceed 30% due to multiple innovative drugs being included in the national medical insurance [1][2] - The company has maintained a strong focus on cost efficiency, resulting in a decrease in expense ratios and a notable increase in net profit margins [3] Revenue and Profitability - In 2025, the company reported innovative drug revenue of 16.34 billion RMB, a 26.1% increase year-on-year, with the contribution from innovative drugs expected to rise significantly in the coming years [1][2] - The company anticipates net profit attributable to shareholders of 9.78 billion RMB in 2026, 12.62 billion RMB in 2027, and 16.64 billion RMB in 2028, reflecting a compound annual growth rate of over 30% [5][11] Cost Management - The company successfully reduced its sales, management, and R&D expense ratios in 2025, leading to an increase in net profit margin to 24.4%, up 1.8 percentage points year-on-year [3] Business Development (BD) Contributions - The company has completed 12 BD transactions from 2023 to 2025, totaling nearly 28 billion USD, which is expected to provide ongoing cash flow [4] - The company has over 30 products in clinical development that are among the top three globally for their respective targets, indicating strong future BD revenue potential [4] Valuation and Forecast - The company is valued at 591.8 billion RMB for A-shares and 650.9 billion HKD for H-shares, with target prices set at 89.16 RMB and 98.06 HKD respectively [5][12]

Group 1 - The core point of the news is the performance of the Shanghai 50 ETF (510800), which opened at 1.351 yuan with a 0.00% change on March 26 [1][2] - The major holdings of the Shanghai 50 ETF include stocks like Kweichow Moutai, Ping An Insurance, and others, with varying performance; Kweichow Moutai down 0.09%, Ping An down 0.02%, and others showing similar declines [1] - The Shanghai 50 ETF has a benchmark performance based on the Shanghai 50 Index return, managed by China Construction Bank Fund Management Co., with a return of 35.13% since its inception on December 22, 2017, but a recent one-month return of -6.44% [2] Group 2 - A MACD golden cross signal has formed, indicating potential upward momentum for certain stocks [3]